Chronic exposure to romantic excitement may dull the effects of dopamine, prompting the brain to crave novelty. Could ...

Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Hutchmed China reported positive interim results from its phase three ‘SACHI’ trial on Monday, showing that the combination ...

Prophet T.B. Joshua predicted post-election turmoil in Nigeria, warning of fearful situations ahead. His prophecy has sparked ...

HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 - 9:00 pm EDT on June 2, 2025). The event will be held in ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer.

Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates ...

BACKGROUND: Dilated cardiomyopathy (DCM) is substantially influenced by genetic factors. Sarcomere function is intricately associated with other organelles, particularly the reciprocal regulation ...

Goldman Sachs 46th Annual Global Healthcare Conference Call June 11, 2025 3:20 PM ETCompany ParticipantsTom Cavanaugh ...